LivaNova (NASDAQ: LIVN) recently received a number of ratings updates from brokerages and research firms:
- 11/28/2018 – LivaNova was downgraded by analysts at ValuEngine from a “strong-buy” rating to a “buy” rating.
- 11/27/2018 – LivaNova is now covered by analysts at UBS Group AG. They set a “neutral” rating and a $105.00 price target on the stock.
- 11/22/2018 – LivaNova was downgraded by analysts at BidaskClub from a “strong-buy” rating to a “buy” rating.
- 11/21/2018 – LivaNova had its “hold” rating reaffirmed by analysts at BTIG Research.
- 11/8/2018 – LivaNova was upgraded by analysts at BidaskClub from a “buy” rating to a “strong-buy” rating.
- 11/1/2018 – LivaNova had its “hold” rating reaffirmed by analysts at BTIG Research.
Shares of NASDAQ LIVN traded down $3.91 during trading on Wednesday, hitting $98.42. 655,914 shares of the company traded hands, compared to its average volume of 630,215. LivaNova PLC has a 1 year low of $76.14 and a 1 year high of $131.54. The stock has a market capitalization of $4.93 billion, a PE ratio of 29.73, a P/E/G ratio of 3.19 and a beta of 0.85. The company has a quick ratio of 1.21, a current ratio of 1.65 and a debt-to-equity ratio of 0.06.
LivaNova (NASDAQ:LIVN) last announced its quarterly earnings data on Wednesday, October 31st. The company reported $0.82 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.90 by ($0.08). LivaNova had a negative net margin of 8.31% and a positive return on equity of 8.77%. The company had revenue of $272.10 million for the quarter, compared to analysts’ expectations of $275.03 million. During the same period in the prior year, the firm earned $0.83 earnings per share. The firm’s quarterly revenue was up 8.3% on a year-over-year basis. Equities research analysts expect that LivaNova PLC will post 3.1 EPS for the current fiscal year.
In related news, insider David S. Wise sold 1,500 shares of the company’s stock in a transaction on Monday, October 15th. The shares were sold at an average price of $112.83, for a total transaction of $169,245.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Daniel Jeffrey Moore sold 1,000 shares of the company’s stock in a transaction on Monday, September 17th. The stock was sold at an average price of $123.49, for a total transaction of $123,490.00. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 8,500 shares of company stock valued at $1,002,355. 0.41% of the stock is owned by corporate insiders.
A number of institutional investors have recently made changes to their positions in the stock. Principal Financial Group Inc. lifted its holdings in LivaNova by 3.0% in the 1st quarter. Principal Financial Group Inc. now owns 191,925 shares of the company’s stock worth $16,985,000 after buying an additional 5,532 shares in the last quarter. Bank of Montreal Can raised its stake in shares of LivaNova by 15.2% in the 2nd quarter. Bank of Montreal Can now owns 4,411 shares of the company’s stock valued at $441,000 after purchasing an additional 582 shares in the last quarter. Massachusetts Financial Services Co. MA acquired a new stake in shares of LivaNova in the 2nd quarter valued at about $788,000. Crossmark Global Holdings Inc. raised its stake in shares of LivaNova by 6.8% in the 2nd quarter. Crossmark Global Holdings Inc. now owns 7,410 shares of the company’s stock valued at $740,000 after purchasing an additional 470 shares in the last quarter. Finally, Wells Fargo & Company MN raised its stake in shares of LivaNova by 31.4% in the 2nd quarter. Wells Fargo & Company MN now owns 1,177,233 shares of the company’s stock valued at $117,511,000 after purchasing an additional 281,610 shares in the last quarter. 87.53% of the stock is owned by hedge funds and other institutional investors.
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates in two segments, Cardiac Surgery and Neuromodulation. The Cardiac Surgery segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, perfusion tubing systems, cannulae and accessories for extracorporeal circulation, and systems for autotransfusion and autologous blood washing, as well as surgical tissue and mechanical heart valve replacements, and repair products for damaged or diseased heart valves.
Further Reading: How does inflation affect different investments?
Receive News & Ratings for LivaNova PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova PLC and related companies with MarketBeat.com's FREE daily email newsletter.